An observational study in Cardiovascular Disease, Coronary Artery Occlusion and Ischemic Heart Disease, sponsored by Terumo Europe N.V.. Active, not recruiting at 52 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Terumo Europe N.V. (part of Terumo Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Myocardial Ischemia with a site in France — 10 open to participants now, 14 under way, none of them phase 3. Myocardial Ischemia · France.
Among the 63 studies in Myocardial Ischemia with a site in France, this one is the 2nd largest by enrollment of the 19 observational ones that give a count, is one of 3 that started in 2023, is one of 19 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 58th registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →10 of the 63 studies in Myocardial Ischemia with a site in France are open now. Recruiting first, the newest first:
Clinique Bizet · Sites in France
Ages 18+ · Healthy volunteers
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
Instituto de Investigación Biomédica de Salamanca · Sites in France, Netherlands, Spain
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–90
Fundación EPIC · Sites in France, Spain, United Kingdom
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 8 · Phase 4 8
First in 2002; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,000 is above the median of 318 across 398 observational studies indexed under Myocardial Ischemia.
Median enrollment 313 across the 43 interventional studies, 1,000 across the 19 observational. Of the 43 that completed or were terminated, 8 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 63 have an industry lead sponsor. The 10 most frequent:
This study is registered under Terumo Europe N.V., one of the names counted as Terumo Corporation. Under that name alone:
Terumo Europe N.V. is the lead sponsor of 25 studies on the registry; 1 is open to participants now.
Terumo Corporation has 1 study filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Ischemia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT07732283Clinique Bizet4-electrode ECG (DigitalCardio®) vs Standard 10-electrode ECG: Evaluating Ease of Use and Recording Quality | 2026-12 |
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
| NCT05698732Fundación EPICCoroflex® ISAR NEO PMCF Study | 2027-02-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 63 studies in Myocardial Ischemia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The NAGOMI COMPLEX PMCF (Post-Market Clinical Follow-up) study has been designed to expand the knowledge about outcomes with the Ultimaster Nagomi™ sirolimus eluting coronary stent system (Ultimaster Nagomi™) in complex PCI subjects. The features for a complex PCI are based upon subgroup analysis of earlier published studies.
The study is a prospective, multi-center, post-market, non-interventional, observational, single-arm study. Subjects with an indication for a PCI according to current European Society of Cardiology (ESC) or national guidelines will be treated with the Ultimaster Nagomi™ in accordance with the intended use. The PCI procedure will be per hospital routine including the option, as per physician preference, to assess the functional severity of the lesion, perform intra-coronary imaging, use lesion preparation devices or to perform a staged procedure. Also, post-procedural anti-platelet medication will be per ESC or national guidelines.
The primary endpoint is Target Lesion Failure (TLF) defined as Cardiovascular Death (CD), Target-Vessel related Myocardial Infarction (TV-MI) and Clinically Driven Target Lesion Revascularization (CD-TLR) at 1 year. Secondary endpoints are a broad set of clinical endpoints defined by the Academic Research Consortium-II to fully characterize the performance of the Ultimaster Nagomi™ stent. Clinical events will be adjudicated by an independent Clinical Events Committee (CEC) to ensure a consistent assessment versus the event definitions. The Data Monitoring Committee (DMC) will simultaneously conduct regular review for accumulating data to ensure proper safety data monitoring. Core lab analysis of the baseline angiograms of bifurcation lesions by Quantitative Coronary Angiography (QCA) will be included. Procedural resource data will be collected for health-economic analysis. Subject reported outcomes will be documented using the EQ-5D-5L questionnaire and the Seattle Angina Questionnaire (SAQ) for the assessment of the quality of life and angina status, respectively.
The study will enroll 3,000 patients from European sites. Follow-up will be 2 years, except for subjects in whom no Ultimaster Nagomi™ stent was implanted and subjects that do not meet the inclusion criteria for a complex PCI as ascertained after the index procedure. These subjects will be followed until discharge.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
This study's enrollment of 3,000 is above the median of 318 across 398 observational studies indexed under Myocardial Ischemia.
Browse Myocardial Ischemia studies →Terumo Europe N.V. is the lead sponsor of 25 studies on the registry; 1 is open to participants now.
Compared within Myocardial Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Subjects who have signed the informed consent are considered enrolled upon insertion of the first Ultimaster NagomiTM stent is successfully implanted and the complex procedure criteria are confirmed. It is expected that study enrolment will take approximately 1.5 years. Enrolment will be competitive, i.e. enrolment will be closed once the total number of subjects has been reached irrespective of the number of subjects per individual site. Individual sites can not enroll more than 300 subjects.
The enrolled patient population is expected to be representative for complex patients because of the limited exclusion criteria and the participation of multiple sites from across Europe
General Inclusion Criteria:
Complex Procedure Inclusion Criteria
Subject meets ≥ 1 of the complex procedure criteria:
i) side branch disease > 10 mm ii) calcified lesion iii) thrombotic lesion
e) Bifurcation lesion implanted with two stents
f) Total stent length implanted > 60 mm
g) Chronic total occlusion defined as a 100% occlusion with antegrade TIMI 0 flow with at least a 3-month duration
h) Left main stenting (main stem and/or bifurcation)
i) In-stent restenosis
j) Severe calcified lesion with use of atherectomy, lithotripsy or cutting balloon
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter
Target Lesion Failure (TLF)
Defined as the composite of cardiovascular death, target-vessel related myocardial infarction and clinically driven target lesion revascularization.
Time frame: at 1-year post procedure
Delivery success
Delivery success is defined as an achievement of successful delivery of study stent to the target lesion, expansion of the study stent and withdrawal of the delivery catheter.
Time frame: Intraoperative
Lesion success
Lesion success is defined as the attainment of \< 30% residual stenosis by visual estimate and/or \< 50% (by QCA) using any percutaneous method (if QCA was not available, the visual estimate of diameter stenosis is used).
Time frame: Intraoperative
Device success
Device Success is defined as delivery success with the achievement of a final residual diameter stenosis of the target lesion of \< 30% by visual assessment and/or \< 50% by QCA, using the assigned device only.
Time frame: Intraoperative
Procedure success
Procedure Success is defined as the achievement of \< 30% residual stenosis by visual assessment in all target lesions using any percutaneous method without the occurrence of death, Q wave or WHO defined non-Q wave, or repeat revascularization of the target lesion during the hospital stay.
Time frame: during hospitalization, approximately 3 days
Target lesion failure (TLF)
The composite of cardiovascular death, MI (not clearly attributable to a nontarget vessel) and clinically driven Target lesion revascularization (TLR).
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Patient oriented composite endpoint (POCE)
Defined as composite of all-cause mortality, any MI and any coronary revascularization.
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Death and subclassifications
Death may be subclassified as: Cardiovascular death, Noncardiovascular death or Undetermined death. Cardiovascular death may include death caused by acute MI, death caused by sudden cardiac death, including unwitnessed, death resulting from heart failure, death caused by stroke, death caused by cardiovascular procedures, death resulting from cardiovascular hemorrhage, death resulting from other cardiovascular cause. Noncardiovascular death may include death from malignancy, death resulting from pulmonary causes, death caused by infection (including sepsis), death resulting from gastrointestinal causes, death resulting from accident/trauma, death caused by other noncardiovascular organ failure, death resulting from other. Undetermined cause of death is defined as a death not attributable to any other category because of the absence of any relevant source documents.
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Myocardial infarction and subclassifications
Myocardial infarction - Absolute rise in cardiac troponin (from baseline) ≥35 times upper reference limit, plus 1 (or more) of the following criteria: * New significant\* Q waves or equivalent * Flow-limiting angiographic complications * New "substantial" loss of myocardium on imaging \* Q-wave criteria requires the development of new Q waves ≥40 ms in duration and ≥1 mm deep in voltage in ≥2 contiguous leads.
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Revascularization and subclassifications
Successful revascularization of all lesions with angiographically a diameter stenosis ≥ 50%
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Stent thrombosis (ST) and subclassifications
Definite ST Presence of a thrombus that originates in the stent/scaffold or in the segment 5mm prox. or dist. to the stent/scaffold or in a side branch originating from the stented/scaffolded segment \& at least 1 of the ff: Acute onset of ischemic symptoms at rest New ECG changes suggestive of acute ischemia Typical rise and fall in cardiac biomarkers Or Pathological confirmation of thrombosis Evidence of recent thrombus within the stent/scaffold determined at autopsy Examination of tissue retrieved ff. thrombectomy Probable ST Any MI that is related to documented acute ischemia in the territory of the implanted stent/scaffold w/out angiographic confirmation of stent/scaffold thrombosis and in the absence of any other obvious cause. Occlusive thrombus Thrombolysis in MI grade 0/1 flow w/in or prox. to a stent/scaffold segment. Nonocclusive thrombus Intracoronary thrombus defined as a noncalcified filling defect or lucency surrounded by contrast material seen in mu
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Bleeding (Bleeding Academic Research Consortium (BARC) 3-5)
Type 3:Clinical, lab, and/or imaging evidence of bleeding w/ specific healthcare provider responses, as below: Type 3a Any BT with overt bleeding Overt bleeding plus Hgb drop ≥3 to \< 5 g/dL Type 3b Overt bleeding plus Hgb drop ≥5 g/dL Cardiac tamponade Bleeding requiring surgical intervention for control Bleeding requiring IV vasoactive drugs Type 3c Intracranial hemorrhage Type 4:CABG-related bleeding Perioperative intracranial bleeding w/in 48 hr Reoperation after closure of sternotomy for bleeding control Transfusion of ≥5 U whole blood or packed RBC w/in a 48-hr period Chest tube output ≥2 L w/in a 24-hr period Type 5:Fatal bleeding Bleeding that directly causes death with no other explainable cause. Categorized as: Type 5a Probable bleeding that is clinically suspicious as the cause of death, but bleeding is not directly observed and no autopsy or confirmatory imaging. Type 5b Definite bleeding that is directly observed (clinical specimen or imaging)
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Balance between bleeding (BARC 3-5) and thrombotic event (myocardial infarction and/or stent thrombosis)
The number of patients with a BARC 3-5 bleeding in comparison to the number of patients with a myocardial infarction and/or a stent thrombosis.
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Utilization of cardiovascular health care resources
Number of devices used during the procedure and use of anti-platelet and anti-thrombotic medication during the follow-up period.
Time frame: at index procedure, 30 days, 6 months, 1 year, and 2 years
Quality of Life assessment
Quality of Life assessed as per EuroQl five-dimensional (EQ-5D) questionnaire: The first part of the questionnaire contain descriptive questions on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, each with 5 levels of responses. The second part of the questionnaire contains a standard vertical 20-cm visual analog scale that is calibrated from 'the worst health you can imagine' (scored 0) at its base to 'the best health you can imagine' (scored 100) at its apex.
Time frame: at baseline, 30 days, 6 months, 1 year, and 2 years
Angina status assessment Seattle Angina Questionnaire (SAQ)
Angina status will be assessed through the Seattle Angina Questionnaire (SAQ). The SAQ is a validated disease-specific instrument for assessing the health status of patients with coronary artery disease. Scoring: Scores range from 1-100 with higher scores indicating better health
Time frame: at baseline, 30 days, 6 months, 1 year, and 2 years
QCA of the index procedure angiogram for a subset of patients with a Complex Bifurcation Lesion (CBL)
Luminal dimensions of bifurcation lesions will be measured by off-line quantitative coronary angiography by a central core laboratory. The objective of the QCA is to quantitate and express the benefit of the Proximal Optimisation Technique (POT). The POT balloon positioning is of importance in this technique as well as the balloon diameter to obtain optimal stent apposition in the main branch.
Time frame: procedure
Ran from Apr 2023 to primary completion in Jul 2026, 38 months.
Of 39 industry-sponsored observational studies under Myocardial Ischemia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 38 months is above that.
Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.